EichorEICHOR
Condition: Leukemia Myelocytic Acute Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Leukemia Myelocytic Acute

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
Phase N/A · 1 location(s) · University Hospital, Angers · NCT07147621High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML
Phase 1 · 1 location(s) · Kittika Poonsombudlert · NCT07177079Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06874257Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06611839CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04662294A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke
Phase 3 · 257 location(s) · Janssen Research & Development, LLC · NCT06852222WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory St
Phase N/A · 1 location(s) · University of Oxford · NCT07511829CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06307054Study of REM-422 in Patients With AML or Higher Risk MDS
Phase 1 · 9 location(s) · Remix Therapeutics · NCT06297941Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07392242Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 · 2 location(s) · Mayo Clinic · NCT06508463Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Phase 3 · 203 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT06652438Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Phase 2 · 5 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07304232Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Terrence J Bradley, MD · NCT05597306Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M
Phase 2 · 12 location(s) · Technische Universität Dresden · NCT06717958225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiati
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06287944Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
EARLY_Phase 1 · 1 location(s) · Base Therapeutics (Shanghai) Co., Ltd. · NCT06541444Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
Phase N/A · 30 location(s) · Acute Leukemia French Association · NCT04777916Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete
Phase 2 · 58 location(s) · Daiichi Sankyo · NCT06824168uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518Home Blood Transfusions
NA · 1 location(s) · Thomas Jefferson University · NCT07121140MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Phase 3 · 53 location(s) · Hutchmed · NCT06387069A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using
Phase 1/Phase 2 · 4 location(s) · M.D. Anderson Cancer Center · NCT06284486Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling,
Phase N/A · 28 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05772559Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly A
Phase N/A · 1 location(s) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di · NCT07420790Characterization of the Mechanisms of Resistance to Azacitidine
Phase N/A · 4 location(s) · Centre Hospitalier Universitaire de Nice · NCT01210274Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.